Summit Therapeutics Inc. — Form 10-Q
Filed July 23, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Summit Therapeutics and Akeso, Inc. executed Amendment No. 3 to their December 2022 Collaboration and License Agreement (effective May 22, 2026), clarifying terms for government-funded, CRADA, and investigator-sponsored clinical studies of AK112. The amendment eliminates mandatory data and biological sample sharing when third-party sponsors restrict access, streamlines publication review timelines (24 hours), permits academic/non-profit institutions to own study inventions, and grants Summit explicit rights to enter Accelerated Clinical Trial Agreements (ACTAs) in the License Territory. No dollar amounts, milestones, or equity changes were disclosed.
Why this rating
Administrative clarification of existing collaboration governance; no financial impact, deal value change, or material business event disclosed. Routine amendment.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.